Paladin gets $1 million in amended deal with Isotechnika; acquires Tempra from for Canada

4 February 2011

Canadian specialty drugmaker Paladin Labs (TSX: PLB) says that it has agreed to amend its partnership with Isotechnika Pharma (TSX: ISA). In order to support a transaction between Isotechnika and ILJIN Life Science for the continued development of voclosporin for transplantation and autoimmune diseases, Paladin has licensed additional territories to Isotechnika.

In consideration for such amendment, Paladin has received $1 million from Isotechnika. Further, Paladin has sold 12.5 million shares of Isotechnika to ILJIN for $3.25 million. Paladin retains its rights to voclosporin for transplantation and autoimmune diseases for Canada, South Africa and Israel in addition to certain rights under the Lux and Atrium licenses and third party manufacturing agreements.

Gets rights to Bristol-Myers pain product

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK